"Personally, I’ve tried to use a lot more NSAIDs and over-the-counter pain medications but there are times where I give very short-course Percocet or Norco to cover a patient for surgery," says one urologist.
Acting based on fear can negatively affect long-term investment performance, write Jeff Witz, CFP, and David Zemon.
Bob Gatty recaps the recent Annual Urology Advocacy Summit in Washington.
To help you sift the enormous scientific program and prioritize your schedule at the AUA annual meeting, the editors have called upon Urology Times’ editorial advisory board to identify the key research across multiple areas of the specialty.
The benefits of bilateral nerve-sparing procedures in men undergoing radical prostatectomy may be concentrated in those patients who have high sexual function at baseline.
Abiraterone acetate (ZYTIGA) should be considered a standard of care for newly diagnosed, metastatic, non-castrate prostate cancer, as should docetaxel (Taxotere), according to a new clinical practice guideline from ASCO.
Nocturia affects more than 40 million adults in the United States yet only 1.5 million are receiving treatment. And while this condition is under-recognized, its impact is very real — resulting in $62.5 billion in healthcare costs each year. What steps can you take to ease the burden for patients who suffer from nocturia?
Data from a recent study also indicate that overactive bladder patients discontinue pharmacotherapy long-term despite chronic symptoms.
Until now there has been no large, thorough investigation into the risk of clean intermittent catheterization in patients undergoing repeat injections of onabotulinumtoxinA.
Findings from a cost-effectiveness analysis provide useful information for physicians, patients, and payers about available treatments for lower urinary tract symptoms due to BPH, according to the authors who conducted it.